Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 3 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

High hs-CRP levels in hyperuricaemic patients linked to increased long-term CHD risk

17 Nov 2019

There appears to be a borderline positive association between high-sensitivity C-reactive protein (hs-CRP) and long-term risk of coronary heart disease (CHD) among middle-aged and elderly individuals with hyperuricaemia, a study reports.

The cross-sectional study evaluated the 10-year CHD risk in 517 hyperuricaemic patients (84.7 percent male) aged 40–85 years in relation to hs-CRP levels. Hyperuricaemia was based on uric acid concentrations: ≥416 μmol/L for males and ≥360 μmol/L for females.

In the cohort, 193 patients (37.3 percent) had relatively high 10-year CHD risk, as measured using the Framingham risk score. The crude odds ratios (ORs) associated with the highest four vs lowest quintile of serum hs-CRP level were as follows: second, 1.43 (95 percent confidence interval [CI], 0.78–2.63; p=0.245); third, 2.05 (95 percent CI, 1.14–3.67; p=0.016); fourth, 2.77 (95 percent CI, 1.54–4.98; p=0.001); and fifth, 2.12 (95 percent CI, 1.18–3.80; p=0.012; p-trend=0.057).

The results did not change significantly following adjustments for several potential confounding factors, although the associations had become only borderline significant. The respective multivariable ORs for 10-year CHD in the second, third, fourth and fifth quintiles of serum hs-CRP level were 1.40 (95 percent CI, 0.75–2.61; p=0.291), 2.05 (95 percent CI, 1.13–3.72; p=0.019), 2.69 (95 percent CI, 1.47–4.89; p=0.001) and 2.10 (95 percent CI, 1.15–3.84; p=0.016) when compared with the lowest quintile (p-trend=0.068).

Despite the need for more research, the findings suggest that hs-CRP could serve as a marker for CHD risk in patients with hyperuricaemia, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 3 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).